PTCT - Conference and earnings call announcements

WARREN, N.J., May 4, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that its executives will speak at the following conferences: Bank of America Securities Health Care Conference 2026Tuesday, May 12 at 8:40 a.m. PDT / 11:40 a.m. EDTRBC Capital Markets 2026 Global Healthcare ConferenceWednesday, May 20 at 10 a.m. EDTGoldman Sachs 47th Annual Global Healthcare ConferenceTuesday, June 9 at 9:20 a.m. EDTThe presentations will be webcast live on the Events and Presentations page under the Investor section of PTC Therapeutics' website at https://ir.ptcbio.co

WARREN, N.J., Dec. 18, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that CEO Matthew B. Klein, M.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026, at 9 a.m. PST/12 p.m. EST. The presentation will be webcast live on the Events and Presentations page of the Investors section of the PTC Therapeutics website at https://ir.ptcbio.com/events-presentations, and it will be archived for 30 days following the presentation. About PTC Therapeutics, Inc.PTC is a global biopharmaceutical company dedicated to the disc

WARREN, N.J., Feb. 20, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that its executives will participate in fireside chats at the following investor conferences: TD Cowen 45th Annual Health Care 2025 Conference  Tuesday, March 4 at 11:10 a.m. ET Barclays 27th Annual Global Healthcare ConferenceTuesday, March 11 at 12:30 p.m. ET The presentations will be webcast live on the Events and Presentations page under the Investor section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the

WARREN, N.J., Dec. 23, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that CEO Matthew B. Klein, M.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 11:15 a.m. PST / 2:15 p.m. EST. The presentation will be webcast live on the Events and Presentations page under the Investors section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the presentation. It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection.  About PTC Therapeutics, Inc.PTC is a global biopharmaceutical co

WARREN, N.J., May 29, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that the company will present a company overview at the following conference: William Blair's 44th Annual Growth Stock ConferenceTuesday, June 4, at 9:00 am ET / 8:00 am CT The presentation will be webcast live on the Events and Presentations page under the Investor section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the presentation. It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection. About PTC Therapeutics, Inc.PTC is a global biopharmaceut

SOUTH PLAINFIELD, N.J., June 29, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that the MIT-E trial of vatiquinone for the treatment of mitochondrial disease associated seizures (MDAS) failed to achieve its primary endpoint of reduction in observable motor seizures. The study showed evidence of treatment effect in reducing seizure frequency in the overall study population and in the largest subgroup of children with Leigh syndrome, in whom benefit was also observed in the key secondary endpoints of occurrence of status epilepticus and disease-related hospitalizations. "We are incredibly grateful to the patients, their families and our investigators who participate

SOUTH PLAINFIELD, N.J., Feb. 2, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that the company will present a company overview at the following conference: SVB Securities Global Biopharma ConferenceTuesday, Feb. 14 at 9:20 a.m. EST The presentation will be webcast live on the Events and Presentations page under the Investor section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the presentation. It is recommended that users connect to PTC's website several minutes prior to the st

SOUTH PLAINFIELD, N.J., Jan. 3, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that management will present a company overview at the 40th Annual J.P. Morgan Virtual Healthcare Conference on Monday, Jan. 10, at 7:30 a.m. EST. The presentation will be webcast live on the Events and Presentations page on the Investor section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the presentation. It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection. About PTC Therapeutics, Inc.PTC is a science-driven, global biopharmaceutica

SOUTH PLAINFIELD, N.J., Nov. 16, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that management will present a company overview at the 4th Annual Evercore ISI HealthCONx Conference on Tuesday, Nov. 30 at 8:25 a.m. ET. The presentation will be webcast live on the Events and Presentations page on the Investor section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the presentation. It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection. About PTC Therapeutics, Inc.PTC is a science-driven, global biopharmaceutical compan

SOUTH PLAINFIELD, N.J., Oct. 26, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that management will present a company overview at the Credit Suisse 30th Annual Healthcare Conference on Tuesday, Nov. 9 at 8:00 a.m. ET. The presentation will be webcast live on the Events and Presentations page on the Investor section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the presentation. It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection. About PTC Therapeutics, Inc.PTC is a science-driven, global biopharmaceutical compa

SOUTH PLAINFIELD, N.J., May 19, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that management will present a company overview at the following conference: William Blair 41st Annual Growth Stock ConferenceWednesday, June 2nd at 3:40 p.m. ET The presentation will be webcast live on the Events and Presentations page under the investor relations section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the presentation. It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection. About PTC Therapeutics, Inc.PTC is a science-dri

SOUTH PLAINFIELD, N.J., April 7, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webinar in its deep dive series discussing the PTC518 Huntington disease (HD) program on Thursday, April 15 at 9 a.m. E.T. The Huntington Disease Deep Dive will provide an overview of PTC's splicing platform and the identification of molecules that have selectivity and specificity. PTC will highlight its Huntington program and the potential advantages of an orally bioavailable compound. PTC will discuss in detail the splicing modifier, PTC518, that is in an ongoing Phase 1 clinical trial. In preclinical studies, PTC518 has demonstrated broad biodistribution that uniformly reaches all regi

SOUTH PLAINFIELD, N.J., Feb. 4, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a conference call today at 5:30 p.m. E.T. to review results from its clinical study 045 of Translarna™ (ataluren) in patients with nonsense mutation Duchenne muscular dystrophy. The webinar can be accessed by dialing (877) 303-9216 (domestic) or (973) 935-8152 (international) five minutes prior to the start of the webinar and providing the passcode 3495760. A live, listen-only webcast can be accessed on the Events and Presentations page under the investor relations section of PTC Therapeutics' website at www.ptcbio.com. The accompanying slide presentation will be posted on the investor rel

SOUTH PLAINFIELD, N.J., Jan. 4, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11th at 7:30 a.m. EST. The presentation will be webcast live on the Events and Presentations page under the investor relations section of PTC Therapeutics' website at www.ptcbio.com and will be archived for 30 days following the presentation. It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection. About PTC Therapeutics, Inc. PTC is a science-driven, global biopharmaceutical company focuse

SOUTH PLAINFIELD, N.J., Dec. 9, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webinar in its deep dive series discussing Translarna on Tuesday, December 15 at 12:00 noon ET. The Translarna Deep Dive will provide an overview of results from the clinical and real-world data generated to date for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in patients 2 years and older. PTC will also review Translarna's commercial success and the potential regulatory milestones in the United States.  As a reminder, the results from Study PTC124-GD-045-DMD will be available in the first quarter of 2021. The webinar can be accessed by dialing (877) 303-9216 (